Abstracts tagged "Janus kinase (JAK)"

Abstract Number: 2565 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Third Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
Peter Nash¹, Laura C. Coates², Alan J. Kivitz³, Philip J. Mease⁴, Dafna D Gladman⁵, Jose A Covarrubias-Cobos⁶, Dona Fleishaker⁷, Cunshan Wang⁷, Elizabeth Kudlacz⁷, Sujatha Menon⁷, Lara Fallon⁸, Thijs Hendrikx⁹ and Keith S Kanik⁷, ¹University of Queensland, Brisbane, Australia, ²University of Oxford, Oxford, United Kingdom, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁶Unidad Reumatologica Las Americas S.C.P, Mérida, Yucatan, Mexico, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Canada, Montreal, QC, Canada, ⁹Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). We report the safety, tolerability, and efficacy of tofacitinib in…
Abstract Number: 1530 • 2018 ACR/ARHP Annual Meeting
CRP Changes during Bacterial Infections in Baricitinib-Treated Patients with RA
Oliver Hendricks¹, Stavros Chrysidis², Jens Gerwien³, Chadi Saifan³, Francesco de Leonardis³, Pedro Lopez-Romero³, Jinglin Zhong⁴, Kevin Winthrop⁵ and Josef S. Smolen⁶, ¹King Chr.Xs Rheumatology Hospital, Graasten, Denmark, ²Rheumatology Department Sydvestjysk Sygehus, Esbjerg, Denmark, ³Eli Lilly and Company, Indianapolis, IN, ⁴Quintiles, Rockville, MD, ⁵Oregon Health Sciences University, Portland, OR, ⁶Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Background/Purpose: Baricitinib (BARI) is a selective inhibitor of Janus kinase 1/2, modulating responses to inflammatory cytokines, e.g. IL-6 or IFNs1. During acute inflammation, including those…
Abstract Number: 2815 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Safety – Update from up to 6 Years of Treatment with Baricitinib in Rheumatoid Arthritis Clinical Trials
Michael Weinblatt¹, Peter C. Taylor², Gerd R. Burmester³, Chadi Saifan⁴, Chad D. Walls⁴, Maher Issa⁴, Terence P. Rooney⁴ and Tsutomu Takeuchi⁵, ¹Brigham and Women’s Hospital, Boston, MA, ²Botnar Research Centre, Univ of Oxford, Oxford, United Kingdom, ³Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Baricitinib (BARI), a selective inhibitor of Janus kinases, is approved in >40 countries for the treatment of active rheumatoid arthritis (RA) in adults. Patients…
Abstract Number: 224 • 2018 ACR/ARHP Annual Meeting
Risk of Venous Thrombotic Events in Rheumatoid Arthritis Patients Initiating Tofacitinib or Adalimumab
Huifeng Yun, Fenglong Xie, Lang Chen and Jeffrey R. Curtis, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Recent concern has been raised for a risk for venous thromboembolism (VTE) associated with janus kinase inhibitors among patients with RA who are already…
Abstract Number: 1536 • 2018 ACR/ARHP Annual Meeting
Mean Platelet Volume Changes with Baricitinib Indicate Reduced New Platelet Production in Baricitinib-Treated Rheumatoid Arthritis Patients
Jon T. Giles¹, Michael T. Nurmohamed², Henry M. Rinder³, Venkatesh Krishnan⁴, Brenda J. Crowe⁴, Chadi Saifan⁴ and Thomas Dörner⁵, ¹Columbia University, New York, NY, ²VU University Medical Center, Amsterdam, Netherlands, ³Yale University School of Medicine, New Haven, CT, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Charité Universitätsmedizin Berlin and Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Germany
Background/Purpose: Transient increases in circulating platelets were observed in patients with RA treated with baricitinib, an oral selective Janus kinase 1/2 inhibitor, approved for the…
Abstract Number: 525 • 2018 ACR/ARHP Annual Meeting
Low Interstitial Lung Disease Event Rate in Patients with Rheumatoid Arthritis: Pooled Post Hoc Analysis of Data from the Tofacitinib Clinical Development Program
Gustavo Citera¹, Eduardo Mysler², Hugo Madariaga³, Mario H Cardiel⁴, Oswaldo Castañeda⁵, Aryeh Fischer⁶, Pascal Richette⁷, Sandra Chartrand⁸, Jin Kyun Park⁹, Sander Strengholt¹⁰, Jose L Rivas¹¹, Amit Thorat¹², Tanya Girard¹³, Kenneth Kwok¹⁴, Lisy Wang¹⁵ and Dario Ponce de Leon¹⁶, ¹Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Organización Médica de Investigación, Buenos Aires, Argentina, ³Clínica del Sur, Arequipa, Peru, ⁴Centro de Investigación Clínica de Morelia, Morelia, Mexico, ⁵Clínica Anglo Americana, Lima, Peru, ⁶Department of Medicine, University of Colorado, Denver, CO, ⁷Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, ⁸Department of Medicine, Hôpital Maisonneuve-Rosemont affiliated to Université de Montréal, Montréal, QC, Canada, ⁹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ¹⁰Pfizer Inc, Capelle aan den IJssel, Netherlands, ¹¹Pfizer SLU, Madrid, Spain, ¹²Pfizer Ltd, Mumbai, India, ¹³Pfizer Inc, Montréal, QC, Canada, ¹⁴Pfizer Inc, New York, NY, ¹⁵Pfizer Inc, Groton, CT, ¹⁶Pfizer Inc, Lima, Peru
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Interstitial lung disease (ILD) is a common extra-articular manifestation of RA,1 and…
Abstract Number: 1586 • 2018 ACR/ARHP Annual Meeting
Expression of JAK Proteins and Autophagy Markers in Sjögren’s Syndrome Patients
María-José Barrera^1,2, Sergio Aguilera³, Isabel Castro², Patricia Carvajal², Sergio González⁴, Claudio Molina¹, Ulises Urzua² and María-Julieta González², ¹Facultad de Odontología, Universidad San Sebastián, Santiago, Chile, ²Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago, Chile, ³Reumatologia, Clinica Indisa, Santiago, Chile, ⁴Facultad de Odontología, Universidad Mayor, Santiago, Chile
Background/Purpose: Sjögren’s syndrome (SS) is an autoimmune epitheliitis that mainly affects the salivary and lachrymal glands. The glandular hypofunction has been associated to loss of…
Abstract Number: 557 • 2018 ACR/ARHP Annual Meeting
The Impact of Comedication with Conventional Synthetic Dmards on Drug Retention and Clinical Effectiveness of Tofacitinib, Anti–Tumor Necrosis Factor Therapy and Biologics with an Alternative Mode of Action in Patients with Rheumatoid Arthritis. a Cohort Study
Axel Finckh¹, Christophe Tellenbach², Almut Scherer², Burkhard Moeller³, Adrian Ciurea⁴, Ines von Mühlenen⁵, Cem Gabay⁶, Diego Kyburz⁷, Ruediger Mueller⁸, Paul Hasler⁹ and Pascal Zufferey¹⁰, ¹University Hospital of Geneva, Geneva, Switzerland, ²SCQM Foundation, Zurich, Switzerland, ³Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, Bern, Switzerland, ⁴Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁵Rheuma-Basel, Basel, Switzerland, ⁶University Hospitals of Geneva, Geneva, Switzerland, ⁷Rheumatology, University Hospital Basel, Basel, Switzerland, ⁸Division of Rheumatology, Kantonsspital St Gallen, St. Gallen, Switzerland, ⁹Kantonsspital Aarau AG, Aarau, Switzerland, ¹⁰Department of Rheumatology, University Hospital Lausanne, Lausanne, Switzerland
Background/Purpose: Co-medication with conventional synthetic DMARDs (csDMARDs) is currently recommended with all targeted therapies (bDMARDs and tsDMARDs) for the management of rheumatoid arthritis (RA). However,…
Abstract Number: 1894 • 2018 ACR/ARHP Annual Meeting
Baricitinib-Associated Changes in Type l Interferon Gene Signature during a 24-Week Phase-2 Clinical SLE Trial
Thomas Dörner¹, Yoshiya Tanaka², Michelle Petri³, Josef S. Smolen⁴, Ernst R. Dow⁵, Richard E. Higgs⁵, Robert J. Benschop⁵, Adam Abel⁵, Maria E. Silk⁵, Stephanie de Bono⁵ and Robert W. Hoffman⁵, ¹Charité Universitätsmedizin Berlin and Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Germany, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁵Eli Lilly and Company, Indianapolis, IN
Background/Purpose: In the phase 2 study JAHH (NCT02708095), treatment with baricitinib (bari), an oral selective Janus kinase 1/2 inhibitor approved for the treatment of RA,…
Abstract Number: 599 • 2018 ACR/ARHP Annual Meeting
Comparative Effectiveness in Pain and HAQ-DI Improvement for Baricitinib Versus Adalimumab, Tocilizumab, and Tofacitinib Monotherapies in Csdmard-Naïve Rheumatoid Arthritis Patients: A Matching-Adjusted Indirect Comparison (MAIC)
Bruno Fautrel¹, Baojin Zhu², Peter C. Taylor³, Mart van de Laar⁴, Paul Emery⁵, Francesco de Leonardis², Carol L. Gaich², Claudia Nicolay², Zbigniew Kadziola², Inmaculada de la Torre⁶ and Roy Fleischmann⁷, ¹University Pierre et Marie Curie, Paris, France, ²Eli Lilly and Company, Indianapolis, IN, ³Botnar Research Centre, Univ of Oxford, Oxford, United Kingdom, ⁴Arthritis Centre Twente, University of Twente, Enschede, Netherlands, ⁵Leeds MSK Biomed/Chapel Allerton Hospital, Leeds, United Kingdom, ⁶Eli Lilly and Company, Madrid, Spain, ⁷Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: In Phase 3 trial (RA-BEGIN), baricitinib (BARI) monotherapy demonstrated superiority to MTX in pain reduction and HAQ-DI improvement in treatment of csDMARD-naïve active RA…
Abstract Number: 2035 • 2018 ACR/ARHP Annual Meeting
Effect of Baricitinib on Joint-Related Biomarkers in Patients with Moderate-to-Severe Rheumatoid Arthritis
Christian S. Thudium¹, Anne C. Bay-Jensen¹, Suntara Cahya², Ernst R. Dow², Morten A. Karsdal¹, Alisa E. Koch², Wenling Zhang² and Robert J. Benschop², ¹Nordic Bioscience, Herlev, Denmark, ²Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (bari) is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK2. In the phase 3 study RA-BUILD (NCT01721057), once-daily bari yielded…
Abstract Number: 887 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Dmards
Yoshiya Tanaka¹, Tsutomu Takeuchi², Sakae Tanaka³, Atsushi Kawakami⁴, Manabu Iwasaki⁵, Yeong Wook Song⁶, Yi-Hsing Chen⁷, Mitsuhiro Rokuda⁸, Hiroyuki Izutsu⁸, Satoshi Ushijima⁸, Yuichiro Kaneko⁸, Teruaki Shiomi⁸ and Emi Yamada⁸, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Nagasaki University, Nagasaki, Japan, ⁴University of Tokyo, Tokyo, Japan, ⁵Yokohama City University, Yokohama, Japan, ⁶Seoul National University Hospital, Seoul, Korea, Republic of (South), ⁷Taichung Veterans General Hospital, Taichung City, Taiwan, ⁸Astellas Pharma, Inc., Tokyo, Japan
Background/Purpose: Peficitinib (ASP015K), a novel oral JAK inhibitor, demonstrated efficacy as once-daily monotherapy in patients with moderate to severe RA in a phase 2b study…
Abstract Number: 2065 • 2018 ACR/ARHP Annual Meeting
Blockade of the JAK/STAT Pathway Inhibits Inflammation and Bone Formation in Two Murine Models of Spondyloarthritis
Yukiko Maeda¹, Zheni Stavre¹, Tingting Huang², Catherine Manning², Bryant Shaughn³, Michael Macoritto³, Deborah Hyland³, Wendy Waegell³ and Ellen M. Gravallese⁴, ¹Medicine, University of Massachusetts Medical School, Worcester, MA, ²Medicine, University of Massachusetts Medical School, worcester, MA, ³Abbvie Bioresearch Center, worcester, MA, ⁴Lazare Research Bldg, University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Spondyloarthritis (SpA) results in significant pain and loss of function due to inflammation and resulting enthesial/periosteal bone formation. Inhibition of the Janus kinase (JAK)/STAT…
Abstract Number: 888 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Methotrexate
Tsutomu Takeuchi¹, Yoshiya Tanaka², Sakae Tanaka³, Atsushi Kawakami⁴, Manabu Iwasaki⁵, Mitsuhiro Rokuda⁶, Hiroyuki Izutsu⁶, Satoshi Ushijima⁶, Yuichiro Kaneko⁶, Teruaki Shiomi⁶ and Emi Yamada⁶, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Nagasaki University, Nagasaki, Japan, ⁴University of Tokyo, Tokyo, Japan, ⁵Yokohama City University, Yokohama, Japan, ⁶Astellas Pharma, Inc., Tokyo, Japan
Background/Purpose: Peficitinib (ASP015K), a novel oral JAK inhibitor, demonstrated efficacy as once-daily monotherapy in patients with moderate-to-severe RA in a phase 2b study (NCT01649999)1. We…
Abstract Number: 2097 • 2018 ACR/ARHP Annual Meeting
Monotherapy with Filgotinib, a JAK1-Selective Inhibitor, Reduces Disease Severity and Alters Immune Cell Subsets in the NZB/W F1 Murine Model of Lupus
Pei Han¹, Christopher Pohlmeyer¹, Ching Shang¹, Zhihua Cui², David Lopez³, Astrid Clarke², Randall Jones², Nevena Mollova³, Igor Mikaelian⁴, David Newstrom³, Shiva Zaboli³, Allyson Shauf³ and Julie Di Paolo⁵, ¹Immunology and Inflammation, Gilead Sciences, Foster City, CA, ²Gilead Sciences, Seattle, WA, ³Gilead Sciences, Foster City, CA, ⁴Biology Core Support, Gilead Sciences, Foster City, CA, ⁵Immunology and Inflammation Biology, Gilead Sciences, Inc., Foster City, CA
Background/Purpose: SLE is a heterogeneous autoimmune disease characterized by immune system hyper-activation leading to the production of autoantibodies and immune attack on multiple organs including…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].